Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phage Therapy for Recurrent UTI
NCT05537519Phase 2Active, not recruiting
- Sponsor
- Unity Health Toronto
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HP3 + HP3.1 + ES19 in urinary tract infection (UTI), sponsored by Unity Health Toronto. Started May 2023; status: active, not recruiting.
02
Drugs
HP3 + HP3.1 + ES19
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT05537519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537519.